Why do some breast cancer patients stop hormone therapy? new study investigates
NCT ID NCT07180914
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 31 times
Summary
This study follows 300 premenopausal women with early-stage HR-positive breast cancer who are already receiving ovarian suppression (OFS) therapy as part of their care. Researchers want to see how many patients continue the therapy for two years and why some stop. The goal is to learn how treatment duration affects long-term outcomes and improve future care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.